MorphoSys, based in Martinsreid near Munich, has been around for a full 27 years, and was until this year led by its co-founder Simon Moroney. He oversaw the patient and painstaking development of the company’s R&D expertise over those decades. The strategy first focused on providing its next-generation antibody technology to big pharma, but MorphoSys now possesses an impressive pipeline of partnered and in-house molecules.
The company has a potential blockbuster on its hands, in the shape of its lead in-house candidate tafasitamab (formerly MOR208),...
